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The knowledge of the etiologic role of high-risk human
papillomavirus (HPV) infection in cervical cancer gen-
erated 2 important clinical tools concerning primary
and secondary prevention: HPV vaccine and HPV DNA
testing, respectively. Although cytology-based screening
has been universally recognized as the cornerstone of
cervical cancer prevention, oncogenic HPV DNA testing
in the last decade has been consistently shown to be
more sensitive (about 930%) than Pap test [1]. Moreover,
randomized trials found that, although some of the cervi-
cal intraepithelial neoplasia 2 (CIN 2) may spontaneously
regress, the increased sensitivity for precancers and can-
cers, grouped here as CIN 3+, is not merely an overdi-
agnosis because there is a corresponding lower incidence
of future CIN 3+ [2Y4]. Increased sensitivity has 2
important clinical outcomes as follows: reduced mor-
tality and an elongation of screening intervals; the latter
implies better compliance with screening and lower costs.
Recent articles supported these assumptions; the New
Technologies for Cervical Cancer screening study showed
that HPV-based screening is more effective than cytology
in preventing invasive cervical cancer, by detecting per-
sistent high-grade lesions earlier and providing a longer
low-risk period. The detection of invasive cervical cancers
was similar for the 2 groups in the first round of screening
(9 in the cytology group vs 7 in the HPV group, p = .62); no
cases were detected in the HPV group during round 2,
compared with 9 in the cytology group (p = .004) [5].
Finally, a recent meta-analysis of 7 European population
studies showed that primary screening by HPV testing
allows for an increase in the interval between 2 screen-
ings of up to 6 years, while keeping the cumulative
incidence rate of CIN 3+ in HPV testYnegative women
almost 2 times lower (0.27%) than in women screened
by cytology (0.51%) at 3-year intervals [6]. In this way,
Reprint requests to: Mario Preti, MD, Corso Orbassano 227, 10137
Torino, Italy. E-mail: mario.preti@tin.it
The authors have declared they have no conflicts of interest.
 2013, American Society for Colposcopy and Cervical Pathology
Journal of Lower Genital Tract Disease, Volume 17, Issue 3, 2013, 362Y365
Copyright © 2013 American Society for Colposcopy and Cervical Pathology. Unauthorized reproduction of this article is prohibited.
even an increase of costs related to the new technology is
balanced by an extension of intervals between 2 different
screens.
Better sensitivity means earlier detection of clinically
relevant cervical lesions and, as a consequence, a re-
duced cancer incidence; therefore, the introduction
in cervical cancer screening programs of primary HPV
DNAYbased screening with cytology triage and repeated
HPV DNA testing of cytology-negative women seems to
be the most feasible strategy [7], minimizing the number
of unnecessary referrals to colposcopy [5].
As a matter of fact, in the very near future, this
approach could be adopted in large-scale pilot studies in
countries where organized cervical cancer screening pro-
grams are well established, starting at the age of 30 years,
moving cervical screening toward better effectiveness and
reproducibility. Such strategy has been recently approved
by the Health Council of the Netherlands [8] as well as
pilot phase in some Italian regions.
In Italy, cervical cancer prevention is pursued through
direct personal invitation by organized triennial regional
screening programs (which cover approximately 60% of
the target population) or via the so-called opportunistic
screening, proposed to a single individual by her family
physician orVmore oftenVprivate gynecologist with a
circa annual periodicity. Overall population coverage
and response rate (70% of the covered population) of
organized screening are still less than optimal, accounting
for approximately 5.6 million of Pap tests per year. On
the other hand, opportunistic cervical screening is a well
established and widely performed preventive intervention
among Italian women, accounting for more than 5 mil-
lion tests taken each year. Although many attempts have
been advocated to discourage opportunistic screening, it
is realistic to expect that it will remain part of our health
preventive scenario for the next years to come.
At this time, a relevant question is how to introduce
the new instances of HPV DNAYbased prevention strat-
egy in these 2 different settings, taking into account the
difficulties existing at this transition time. Indeed, at the
national levelVorganized programs, it will be easyVand
mandatoryVto implement the evidence-based approach
with HPV DNA testing as the primary step and long-time
interval (3Y5 years and more) between the rounds,
whereas in the opportunistic setting, one may expect to
encounter more resistance, considering the tendency to
overscreen patients with conventional cytology, every 12
months (or even less) [9]. This translates to higher costs,
increase in harms, no additional benefits, and treatment of
transient lesions. Human papillomavirusYbased screening,
adopting longer interval (3Y5 years), can interrupt that
financially driven strategy and a discrete effort to achieve
substantial changes in the private setting.
Therefore, it is not unrealistic to anticipate in the near
future a somehow ‘‘double-track’’ scenario in cervical
cancer prevention (public vs private), with different
methods used and uncoordinated interval timing: HPV
DNA testing every 5 years versus annual conventional
Pap test. There is no doubt that such scenario could be
harmful from a public health point of view, would pos-
sibly limit the expected results of cervical cancer preven-
tion, and, even more, could confuse the public opinion and
perception of the tests. There is basically a single option to
counteract such a situation, and it is, during these years
of transition, to strongly support the use of the 2 tests
together (Pap test and HPV DNA testing) in the oppor-
tunistic screening set.
The so-called cotesting strategy (although approved
and supported as optimal primary screening in the
United States for women 30Y65 years [10]) has been re-
cently judged ineffective in organized screening, mainly
owing to overreferral to colposcopy of women presenting
a low incidence of cervical lesions [11] (i.e., cytology-
positive, HPV-negative women), thus resulting in a un-
favorable cost-benefit ratio. Although this perspective
is reasonable at a national, cost-conscious level, in the
privateVopportunisticVarena, the exclusion of an inva-
sive disease in that single woman requiring the test is
the primary goal, and costs might not be the only variable
to be taken into account. In fact, even those few cases of
high-grade cervical lesions testing negative for HR HPV
DNA are important at the individual screening level.
Indeed, in all studies published so far, double testing
resulted in an increased detection of cancer precursor
lesions, either CIN 2+ or CIN 3+. In the ATHENA study,
Castle et al. [11] reported 2 (12.5%) of 16 in situ ade-
nocarcinomas and 20 (4.8%) of 411 CIN 2+ found in
liquid based cytology-positive+/HPV-negative patients. In
similar group of patients in Kaiser Permanente Northern
California study, Katki et al. [12] showed a nonnegligi-
ble rate of squamous cervical cancers (8 of 49, 16.3%)
and of CIN 2+/in situ adenocarcinoma (91 of 2,223;
4.1%). Although cytology is much more useful in HPV-
positive rather than HPV-negative women, the identifica-
tion of such ‘‘extra’’ high-grade lesions in the latter group
(adding cytology) fits into the clinical objective of indivi-
dual screening.
It is important to emphasize that, within the cotest-
ing strategy, an option to reduce unnecessary referrals
to second-level procedures in women at low-risk of
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significant disease (Pap positive/HPV negative) could be
to send to colposcopy only those presenting high-grade
squamous intraepithelial lesion, atypical squamous cells-
cannot exclude high grade lesion, or atypical glandular
cells cytology. Exclusion of borderline cytology (atypical
squamous cells of undetermined significance and low-
grade squamous intraepithelial lesion) from further exam-
ination reduces, in such a group of patients, management
costs, improving overall positive predictive value. In addi-
tion, 2 factors should be taken into account: in the study
published by de Sanjose et al. [13], only 62% of invasive
cervical adenocarcinomas had positive HPV test results.
It is anticipated that approximately one half of the
cervical adenocarcinoma that are currently diagnosed
by cytology would be missed by the introduction of
HPV testing alone. These numbers have minor impact in
population screening, which is directed to the most fre-
quent types of cervical cancer, the squamous and ade-
nocarcinoma HPV-related cervical cancers, but represent
not only a loss of diagnostic chance for the individual
woman who planned and asked to undertake Pap testing
and instead will receive an HPV DNA test, with all the
pluses of the new tool, but also the potential disadvantage
of missing some rare types of cervical cancer.
In conclusion, according to the existing double-track
screening, the introduction of a cotesting strategy in the
opportunistic setting (HPV DNA test and cytology, pre-
ferably on the same vial of liquid based cytology) could
potentially represent the best option to overcome the
challenges related to the transition time from cytology to
HPV DNAYbased screening, giving some homogeneity
between the 2 existing screening scenarios. In the HPV-
negative group, the indication to refer to colposcopy
patients with high-grade squamous intraepithelial lesion
(and atypical squamous cells-cannot exclude high grade
lesion/atypical glandular cells) cytology will result in more
cost-effective management. Moreover, this combined stra-
tegy could also be well accepted by cytopathologists. In the
meantime, private gynecologists will educate themselves
to bypass the habit of annual Pap testing and will appre-
ciate different reasons to see the woman regularly; they
will learn how to manage HPV DNA positivity and be-
come experts in HPV counseling. This will help everyone
be prepared to switch to the next steps, every 5 years
HPV DNAYbased cervical cancer screening and screening
of the vaccinated population.
Human papillomavirus testing carries better protec-
tion against cervical cancer, a real advantage to women’s
health. Any strategy that can smooth and speed up the
adoption of the new technology by gynecologists will result
in a quicker transfer of scientific evidence to women
and better care for them. Supplementation of Pap smear
screening with HPV testing is the fastest track to achieve
this goal, despite the fact that epidemiologic evidence says
that HPV testing can do equally well alone, without
cytology.
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